UEG 2026 at a glance
UEG Week 2026, taking place October 17–20 in Barcelona, brings emerging competitive dynamics into focus across inflammatory bowel disease (IBD), gastrointestinal fibrosis, eosinophilic esophagitis (EoE), metabolic liver disease and AI-enabled diagnostics.From inflammation control to disease modification, the gastroenterology competitive landscape is evolving. LucidQuest examines the clinical developments, emerging therapies and strategic questions that could influence treatment differentiation, market positioning and clinical adoption.
📅 Build your schedule around the topics that matter most.
📥 Download the UEG_2026_Preview_by_LucidQuest
UEG Week 2026: Key Gastroenterology Developments to Watch
Next-Generation IBD Therapies: Competition Expands Beyond Established Treatments
TL1A antibodies, oral IL-23 inhibitors and dual-target therapies could expand treatment options for patients who remain refractory to established therapies. Emerging evidence will help clarify whether these approaches offer meaningful differentiation in efficacy, durability and patient selection.
Crohn’s Disease Fibrosis: Anti-Fibrotic Efficacy Emerges as a Differentiator
STENOVA, INTERACT and emerging therapeutic agents bring intestinal fibrosis into focus as a potential treatment target in Crohn’s disease. A key question is whether these programmes can establish measurable anti-fibrotic endpoints and demonstrate benefits beyond inflammation control.
Deeper IBD Remission: New Treatment Targets Could Reshape Clinical Strategies
VERDICT and STRIDE-III could influence how deeper remission is defined, monitored and incorporated into treatment decisions. Their implications extend to therapeutic positioning, monitoring strategies and treatment escalation in IBD.
Eosinophilic Esophagitis: Competition Shifts Toward Durable Control
Tezepelumab, dupilumab and long-acting corticosteroid programmes will inform competitive differentiation in EoE. Particular attention will focus on sustained disease control and the management of fibrostenotic complications.
Competitor and industry signals: Pharma Strategies and Emerging GI Therapies
TL1A Inhibitors: Roche, MSD and Teva Explore Disease Modification
TL1A-focused sessions involving Roche, MSD and Teva Pharmaceuticals will examine the potential for disease modification and anti-fibrotic positioning. Evidence supporting these benefits could become an important competitive differentiator.
Dual-Target IBD Therapies: AbbVie and Johnson & Johnson Advance New Strategies
ABBV-466 and JNJ-78934804 highlight emerging dual-target and co-antibody strategies in refractory IBD. Their development raises questions about whether broader pathway targeting can translate into clinically meaningful advantages over established treatment approaches.
Novel Oral Therapies: Efficacy and Convenience Drive Differentiation
Icotrokinra, emvistegrast and obefazimod will provide evidence relevant to efficacy, durability and treatment convenience. Competitive positioning will depend on whether these therapies demonstrate advantages that justify their place in increasingly complex treatment pathways.
MASH and MASLD: Gastroenterology Expands Into Metabolic Care
Sessions involving Madrigal Pharmaceuticals and Boehringer Ingelheim highlight the growing intersection of gastroenterology, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
These developments signal potential opportunities for GI-led metabolic care, alongside questions about patient identification, treatment integration and commercial positioning.
Artificial Intelligence and Machine Learning at UEG Week 2026
AI in Endoscopy: From Detection Accuracy to Clinical Utility
Randomised studies of computer-aided detection and diagnosis (CADe/CADx) will examine lesion detection, diagnostic performance and clinical implementation.
The strategic question is whether improvements in diagnostic accuracy translate into measurable benefits in clinical workflows and patient outcomes.
Precision Gastroenterology: AI-Driven Monitoring and Prediction
AI-assisted IBD scoring, flare prediction and large language model applications highlight emerging opportunities for more precise disease monitoring and clinical decision support.
Clinical validation, regulatory readiness and clinician oversight remain critical considerations for broader adoption.
What to Watch After UEG Week 2026: Clinical Evidence and Competitive Differentiation
LucidQuest will be watching three developments:
- Disease modification and fibrosis: Whether TL1A and anti-fibrotic programmes demonstrate meaningful clinical differentiation beyond inflammation control.
- Emerging treatment strategies: Whether novel oral and multi-target therapies deliver convincing efficacy and durability in refractory patient populations.
- AI-enabled gastroenterology: Whether AI applications progress beyond diagnostic performance to measurable improvements in clinical workflows and patient outcomes.
Download the UEG 2026 Preview Report
Download LucidQuest’s ECNP 2026 preview report for deeper analysis of emerging psychiatric therapies, clinical developments and competitive signals.
📅 Build your schedule around the sessions that matter most.
📥 Download the UEG_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
